title: Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.
abstract: Quality of life (QoL) impairment and fatigue are frequently experienced during treatment for recurrent high-grade glioma (HGG). Fatigue and QoL impairments can be due to primary neurological dysfunction, cytotoxic treatments, mood disturbances, and supportive medications. We now seek to understand how QoL and fatigue impacts survival in recurrent HGG. Using a prospective observational design, 237 patients with recurrent HGG and KPS ≥70 completed a self-administered questionnaire that evaluated QoL and fatigue. QoL was assessed with Functional Assessment of Cancer Therapy-General (FACT-G) and FACT-Brain (FACT-Br) scales while fatigue was assessed using Functional Assessment of Chronic Illness Therapy (FACIT-F) scale. Cox proportional hazard models were utilized to evaluate the association between QoL and fatigue and survival. Seventy-three (31 %) subjects had recurrent WHO grade III gliomas and 164 (69 %) had recurrent WHO grade IV gliomas. Median follow-up analysis was 27.60 months. In univariate Cox analyses, the FACT-Br specific subscale (HR 0.88; CI 95 %, 0.77-1; p = 0.048) and FACIT-F (HR 0.82; CI 95 %, 0.68-0.99; p = 0.045) were both significant predictors of survival. Fatigue added prognostic information beyond that provided by KPS, age, sex, tumor grade, and number of prior progressions (HR 0.80; CI 95 %, 0.68-0.9; p = 0.031). A greater degree of fatigue was associated with poorer survival in recurrent HGG patients. In multivariable analyses, FACT-G and FACT-Br are not independent predictors of prognosis. Fatigue is a strong independent predictor of survival that provides incremental prognostic value to the traditional markers of prognosis in recurrent HGG. Pharmacological or non-pharmacological strategies to treat fatigue warrant investigation.
authors.affiliation: Department of Neurology, Duke University Medical Center, Durham, NC, 27710, USA, katherine.peters@duke.edu.
authors.forename: Katherine B
authors.initials: KB
authors.lastname: Peters
authors.forename: Miranda J
authors.initials: MJ
authors.lastname: West
authors.forename: Whitney E
authors.initials: WE
authors.lastname: Hornsby
authors.forename: Emily
authors.initials: E
authors.lastname: Waner
authors.forename: April D
authors.initials: AD
authors.lastname: Coan
authors.forename: Frances
authors.initials: F
authors.lastname: McSherry
authors.forename: James E
authors.initials: JE
authors.lastname: Herndon
authors.forename: Henry S
authors.initials: HS
authors.lastname: Friedman
authors.forename: Annick
authors.initials: A
authors.lastname: Desjardins
authors.forename: Lee W
authors.initials: LW
authors.lastname: Jones
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000401:mortality* / Q000473:pathology / Q000523:psychology* / Q000628:therapy; D005221:Fatigue / Q000209:etiology* / Q000523:psychology; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000401:mortality* / Q000473:pathology / Q000523:psychology* / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011788:Quality of Life; D016879:Salvage Therapy; D011795:Surveys and Questionnaires; D055815:Young Adult